Boston Scientific Corporation (BSX) — closed signal from July 14, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 12, 2025.
Predicted vs. what happened
What happened
Reached 40% of the predicted growth at its peak, without hitting the target.
The thesis — published July 14, 2025
U.S. health regulators just gave wider approval for FARAPULSE, a heart-treatment device made by Boston Scientific. That green light should create a new flow of sales at the same moment the stock price looks beaten down after a recent slide. Trading activity shows far fewer people willing to sell and many more stepping in to buy. With doctors starting to use the product and medical-technology funds likely to return, we see the shares climbing about 12% over the next three months while the company’s other new products keep interest high.
Primary drivers
- Wider FDA approval for FARAPULSE could add a new stream of heart-care sales.
- Stock looks oversold; heavy recent buying hints it may soon change direction.
- Very positive market mood and strong past returns attract big professional buyers.
- Many products in development mean growth is not tied to just one device.
How it played out
BSX: target missed after a 4.8% peak gain
Lyra published BSX at $104.51 on 2025-07-14 with about 12% expected growth over the short term. The thesis pointed to wider U.S. approval for FARAPULSE, an oversold setup with heavy buying, positive market mood, professional buyer interest, and a broader product pipeline.
Inside the window, BSX rose to $109.50 on 2025-09-09. That was a 4.8% peak gain, but it stayed below the $117.05 target. It never got there. The window ended at $95.41 on 2025-10-12, so the published thesis only partially played out.
What happened during the window
On 2025-07-23, Investor's Business Daily reported Boston Scientific's second-quarter results, including $5.06 billion in sales and adjusted earnings of $0.75 per share. The same article said Farapulse U.S. growth was 117%.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.